CRSP icon

CRISPR Therapeutics
CRSP

Overview Fund Activity

182 hedge funds and large institutions have $1.13B invested in CRISPR Therapeutics in 2019 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 51 increasing their positions, 51 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
182
Holders Change
+1
Holders Change %
+0.55%
% of All Funds
4%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.11%
New
31
Increased
51
Reduced
51
Closed
29
Calls
$23.9M
Puts
$22.9M
Net Calls
+$1.02M
Net Calls Change
-$3.18M

Top Buyers

1
NAMA
1
Nikko Asset Management Americas
New York
$114M
2
O
2
OrbiMed
New York
$21.2M
3
CAM
3
Cormorant Asset Management
Massachusetts
$44.4M
4
Lord, Abbett & Co
4
Lord, Abbett & Co
New Jersey
$14.6M
5
AC
5
Armistice Capital
New York
$10.8M

Top Sellers

1
EC
1
EcoR1 Capital
California
$0
2
A
2
Abingworth
United Kingdom
$25.7M
3
Wellington Management Group
3
Wellington Management Group
Massachusetts
$40.2M
4
JPMorgan Chase & Co
4
JPMorgan Chase & Co
New York
$188K
5
Balyasny Asset Management
5
Balyasny Asset Management
Illinois
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
AG
201
Aperio Group
California
– -$153K -3,247 Closed
GAM
202
Griffin Asset Management
New York
– -$64K -1,360 Closed
EWM
203
Executive Wealth Management
Michigan
– -$10K -215 Closed
BCA
204
Berman Capital Advisors
Georgia
– -$9K -200 Closed
YWP
205
YorkBridge Wealth Partners
New York
– -$5K -100 Closed
MF
206
Manchester Financial
California
– -$4K -75 Closed
TCM
207
Tradewinds Capital Management
Washington
– -$3K -65 Closed
TPWA
208
TRUE Private Wealth Advisors
Oregon
– -$2K -48 Closed
5 6 7 8
9